Juno Therapeutics Inc
Most Recent
What Else Could Drive Gilead’s Long-Term Growth?
In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.
Celgene to Acquire Juno Therapeutics
On January 22, 2018, Celgene and Juno Therapeutics announced a merger agreement in which the former will acquire the latter’s business.
An Overview of Celgene’s Hematology and Oncology Pipeline
In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).
How Are XBI’s Holdings’ Moving Averages Trending?
On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.
Agios Stock Rises on Higher Trading Volumes on June 8
Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.
IBB Holdings: How Are Their Moving Averages Trending?
The iShares Nasdaq Biotechnology ETF (IBB) has 189 stocks in its portfolio. As of June 6, 2016, 87% of IBB’s stocks were trading above their 20-day moving averages.
IBB’s Mid-Cap Stocks: Kite Pharma Drug Gets Orphan Drug Status
IBB’s mid-cap holding Kite Pharma (KITE) rose by 3.3% on the news of the FDA granting orphan drug status to Kite’s KTE-C19.
XBI’s Mid Caps: Ionis Gives Update on Nusinersen Phase 2 Study
The mid-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 1% on April 20, 2016. Within XBI, Ionis Pharmaceuticals’ stock closed at $43.62 on the day.
XBI Mid-Cap News: Look Who Took a Beating on March 23
Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.
Analyzing Juno Therapeutics’ Performance until September 2015
Juno Therapeutics (JUNO) is a mid-cap stock with a market cap of ~$4.75 billion. The stock rose by 8.6%. It outperformed all of the biotech stocks.
Kite Pharma and Juno Therapeutics Led Biotechnology Sector
Kite Pharma and Juno Therapeutics led the Biotechnology group of the SPDR S&P Biotechnology ETF (XBI) for the week ending September 11. Kite Pharma and Juno Therapeutics rose 21.94% and 19.78%, respectively.